{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=44",
    "query": {
      "intervention": "cohort 4",
      "page": 44
    },
    "page_size": 10
  },
  "pagination": {
    "page": 44,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=45&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=43&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:48:29.456Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03334851",
      "title": "Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "PF-06835375",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 74,
      "start_date": "2017-11-17",
      "completion_date": "2022-02-15",
      "has_results": true,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 17,
      "location_summary": "Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03334851"
    },
    {
      "nct_id": "NCT06194929",
      "title": "Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Melanoma",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Defactinib",
          "type": "DRUG"
        },
        {
          "name": "Avutometinib",
          "type": "DRUG"
        },
        {
          "name": "Encorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2024-03-20",
      "completion_date": "2030-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06194929"
    },
    {
      "nct_id": "NCT00796796",
      "title": "Temsirolimus and Radiation for Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2009-03",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2013-07-11",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00796796"
    },
    {
      "nct_id": "NCT04491877",
      "title": "Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infection"
      ],
      "interventions": [
        {
          "name": "RSV vaccine formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV vaccine formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Months",
        "sex": "ALL",
        "summary": "6 Months to 18 Months"
      },
      "enrollment_count": 259,
      "start_date": "2020-09-17",
      "completion_date": "2023-04-13",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 25,
      "location_summary": "Gardena, California • La Mesa, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Gardena",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Blackfoot",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04491877"
    },
    {
      "nct_id": "NCT07566377",
      "title": "Cord Blood Transplantation in Children and Young Adults With Blood Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Myelodysplastic Syndromes",
        "Non-hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Leukemia",
        "Lymphoma",
        "Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Cord Blood Units",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "Up to 26 Years"
      },
      "enrollment_count": 71,
      "start_date": "2026-04-28",
      "completion_date": "2030-04-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07566377"
    },
    {
      "nct_id": "NCT03016377",
      "title": "Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Immune System Diseases",
        "Immunoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "iC9-CAR19 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "3 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2012-03-22",
      "completion_date": "2037-09-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016377"
    },
    {
      "nct_id": "NCT01091142",
      "title": "Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "NP001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neuraltus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 56,
      "start_date": "2010-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-10-06",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Kansas City, Kansas • Lexington, Kentucky",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01091142"
    },
    {
      "nct_id": "NCT04580654",
      "title": "A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "CSL312",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2020-10-29",
      "completion_date": "2021-05-07",
      "has_results": false,
      "last_update_posted_date": "2022-10-04",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04580654"
    },
    {
      "nct_id": "NCT04676646",
      "title": "Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperkalaemia",
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Sodium zirconium cyclosilicate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 366,
      "start_date": "2021-03-08",
      "completion_date": "2024-07-15",
      "has_results": true,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 12,
      "location_summary": "Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Hazel Crest",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676646"
    },
    {
      "nct_id": "NCT03873805",
      "title": "PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2019-08-20",
      "completion_date": "2027-03-18",
      "has_results": true,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-11-19T08:48:29.456Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03873805"
    }
  ]
}